Verenium Reports Financial Results for the Third Quarter 2010: Loss Per Share of $0.19

Verenium Corporation VRNM, a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the third quarter of 2010. "I am pleased with the significant progress made across the business over the last quarter; we continue to see solid progress growing and diversifying our product sales and improved performance at the gross margin level," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "Further, we remain committed to using our financial resources to accelerate the development of our current products and our pipeline." Loss Per Share of $0.19